PharmacovigilanceOfficial

Medtronic issues Vanta programmer software with firmware fix for neurostimulator failure after cardioversion

🇳🇱 IGJ · Sun 08 Nov 2026

Medtronic has released clinician programmer software 2.1.4148, which includes a firmware update addressing a previously reported fault in which the Vanta implantable neurostimulator stops working after cardioversion.

Medtronic has released version 2.1.4148 of the clinician programmer application (CPA) for its Vanta neurostimulator, model A71200, according to a notice published by the Dutch health inspectorate IGJ. This version and later ones contain a firmware update.

The update is intended to resolve a problem previously reported from clinical use: the Vanta implantable neurostimulator (INS) ceasing to function after cardioversion. The notice does not give further technical detail on the cause or on how often the fault has occurred.

The field safety notice (FSN) is dated 5 November 2026 and was posted by IGJ with a date of 9 November 2026. The manufacturer is Medtronic Inc, and its authorised representative is Medtronic B.V. The product is listed as Vanta with AdaptiveStim Technology. The accompanying PDF runs to three pages.

IGJ explains that manufacturers must monitor devices after they reach the market and improve them where necessary. Where users are at risk, the manufacturer must act and inform both users and the inspectorate through a field safety notice. The excerpt available does not describe any further customer actions, patient-management advice or the number of devices affected.

What it means for your team

  • Teams with Vanta devices in their portfolio or clinics should read the full FSN to confirm the required actions, as the available text does not set them out.
  • Check that clinician programmers are running CPA version 2.1.4148 or later, since the firmware update is delivered through that software.
  • Vigilance teams should track the cardioversion-related failure mode against existing incident reports and any follow-up from the manufacturer or authorities.
  • Quality and regulatory staff should confirm how the notice is being recorded in field-action and distribution records, including the role of Medtronic B.V. as authorised representative.

Official source: IGJ ↗

Article written by VigiEye from the official source (IGJ). AI-assisted; check the source before acting.

More Pharmacovigilance All →